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Background: Studies determining the development of a wide variety of different comorbid disorders in
inflammatory arthritis (IA) patients are scarce, however, this knowledge could be helpful in optimising preventive
care in IA patients. The aim of this study is to establish the risk that new chronic comorbid disorders in newly
diagnosed patients with IA in a primary care setting are developed.
Methods: This is a nested-case–control study from 2001–2010 using data from electronic medical patient records
in general practice. In total, 3,354 patients with newly diagnosed IA were selected. Each patient was matched with
two control patients of the same age and sex in the same general practice. The development of 121 chronic
comorbid disorders of index and control patients was compared using Cox regression.
Results: After a median follow-up period of 2.8 years, 56% of the IA-patients had developed at least one
chronic comorbid disorder after the onset of IA, compared to 46% of the control patients (p < 0.05). The most
frequent developed comorbid disorders after the onset of IA were of cardiovascular (23%), and musculoskeletal (17%)
origin. The highest hazard ratios (HRs) were found for anaemia (HR 2.0 [95% CI: 1.4-2.7]) osteoporosis (HR 1.9 [1.4-2.4]),
and COPD (HR 1.8 [1.4-2.3]).
Conclusion: Patients with IA developed more chronic comorbid disorders after the onset of IA than one might expect
based on age and sex. Since comorbidity has a large impact on the disease course, quality of life, and possibly on
treatment itself, prevention of comorbidity should be one of the main targets in the treatment of IA patients.
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Inflammatory arthritis (IA) is defined as a group of
chronic rheumatic diseases, including rheumatoid arthritis
(RA), psoriatic arthritis (PsA) and ankylosing spondylitis
(AS). These are all auto-immune diseases characterized by
inflammation of joints and structural changes of bone and
cartilage, with similar treatments. The prevalence of IA
in general practice was 4.8 per 1000 patients in the
Netherlands in 2011. In an average Dutch general practice
around 2350 patients are listed, so approximately 12 pa-
tients with IA are listed in a general practice.* Correspondence: j.ursum@nivel.nl
1NIVEL (Netherlands Institute for Health Services Research), PO Box 1568,
Utrecht 3500, BN, the Netherlands
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reproduction in any medium, provided the orLike many patients with a chronic disease, the majority
of patients with IA have at least one other chronic dis-
order, the observed percentages ranged from 16 to 34%
[1-5]. Several chronic diseases such as cardiovascular
diseases [6,7] pulmonary diseases [8] and gastrointestinal
diseases [9] are known to be increased present in IA pa-
tients [10-12]. The impact of comorbidity is high, as
more chronic diseases result in more disability and di-
minished health related quality of life [13]. Additionally,
(multiple) comorbid conditions in IA patients often lead
to worse clinical outcomes [14].
Longitudinal studies in community-based settings es-
tablishing the development of a wide variety of different
comorbid disorders in IA patients are scarce [15,16]. Up
to now most studies addressing IA patients focus eitherLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or one group of disorders. Moreover, limited attention is
paid to the question whether the observed frequency of
newly developed chronic disorders is higher than one
might expect based on age and sex, since a suitable con-
trol group is often lacking.
A few studies have indicated that the increased risk of
developing new chronic diseases in IA patients might be
due to a possible lack of optimal preventive care [17-19].
Therefore, it could be helpful for optimising preventive
care in IA patients to know the increased risk for a
broad variety of comorbid diseases.
This study aims to establish the risk that new chronic
comorbid disorders in newly diagnosed patients with IA
in a primary care setting are developed.
Methods
Study population
The Dutch Primary Care Database [20] is a network of,
on average, 83 general practices with about 335,000 reg-
istered patients and it was started in 1994. General Prac-
titioners (GPs) record medical information from patients
routinely in electronic medical records (EMR), using the
International Classification of Primary Care – version 1
(ICPC). The ICPC is a classification method for primary
care encounters, accepted by the WHO [21,22]. EMRs
contain information on consultations, morbidity, pre-
scriptions, and referrals to other healthcare profes-
sionals. We have used data from the period 2001–2010.
Available data are representative for the whole Dutch
population [20].
Selection of IA patients and controls
We have selected all newly diagnosed patients with
inflammatory arthritis (IA) aged >30 years, based on
ICPC-code L88 - Rheumatoid arthritis and related disor-
ders [21,22]. A selection purely based on this code could
contain some non-IA patients, so we applied a well-
established algorithm to exclude non-IA patients [23].
Based on this algorithm patients were included if they
had a combination of specific anti-rheumatic drug pre-
scriptions, or if they had more than one visit to their GP
with code L88, or were 60 years or younger. To ensure
that only newly diagnosed IA patients were included,
we excluded patients with an L88-code within 365 days
from start of registration. This was based on the assump-
tion that all IA patients will go to their GP at least once a
year for IA-related complaints.
To determine whether IA patients develop more
chronic diseases than might be expected based on age
and sex, we matched all IA-patients (index patients) with
two control patients (non-IA patients, i.e. patients with-
out an ICPC code L88) from the same general practice.
The controls were matched regarding age (timeframe of5 years) and sex. The date of diagnosis of IA was taken
as the date of inclusion of the matched control. Both
index and control patients were only included if they
had at least 90 days of follow-up.
Chronic diseases and diagnostic clusters
The onset of one hundred and twenty-one chronic
diseases was determined based on a study of O’Halloran
et al., Additional file 1 [24]. All these ICPC codes were
categorised within 17 ICPC chapters, such as cardiovascu-
lar, respiratory or neurological diseases (further called
‘main disease groups’). Additionally, separate ICPC codes
do not always give a complete picture of the disease,
therefore, certain ICPC codes were combined into diag-
nostic clusters, for example uncomplicated hypertension
(K86) and complicated hypertension (K87) were com-
bined. These clusters were based on the selection of
chronic diseases of the National Institute of Public Health
and the Environment from the Netherlands [25] and the
Second Dutch National Survey of General Practice [26].
An overview of the fifteen used diagnostic clusters is pre-
sented in Additional file 2.
Statistical analysis
Only chronic comorbid disorders with a prevalence of at
least 2% are presented. Gout (T92), psoriasis (S91) and
osteoarthritis (OA) (diagnostic cluster) were excluded
from the analysis, because these diseases may be interre-
lated to IA. All chronic comorbid disorders diagnosed
after inclusion were indicated as newly developed. The
development of new chronic diseases was tested in IA
patients and control patients with a Chi-square test.
Thereafter, we applied multivariable Cox regression ana-
lyses, adjusting for age, sex and number of prevalent
chronic diseases at baseline, to determine the difference
between IA and control patients. We performed sensitiv-
ity analyses, limiting the multivariable Cox regression
analysis to 1) cases and matched controls with at least
one year of follow-up, and 2) including only new chronic
comorbid disorders diagnosed 90 days after inclusion.
The latter restriction was chosen because the exact date
of onset of chronic diseases is not always clear. A diag-
nosis made 90 days or more after the diagnosis IA is
very likely to be an onset after the onset of IA. Finally,
logistic regression was performed, by filling in the re-
gression equation, and the absolute change for develop-
ing a chronic disease was calculated.
All statistical analyses were performed with Stata/SE
12.1 (StataCorp, College Station, TX, USA).
Ethical approval
The study was carried out according to Dutch legislation
on privacy. The privacy regulation of the study was regis-
















Number of newly developed chronic diseases after inclusion
Index patient
Control
Figure 1 Percentage of patients who developed new chronic
diseases after inclusion.
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approval by a medical ethics committee was obligatory for
observational studies.
Results
We identified 3,356 patients with IA and matched 6,708
controls. The baseline characteristics are shown in Table 1.
Nearly two-thirds of the patients were female (64%), the
mean age was 55 years (SD = 15) and median follow-up
duration was 2.8 years.
The number of new chronic comorbid disorders
differed significantly between IA and control patients
(p = 0.001, Figure 1). In total, 56% of the IA patients
developed one or more chronic comorbid disorder after
the diagnosis of IA, compared to 46% of the control pa-
tients (Figure 1). One quarter of the IA patients developed
one chronic comorbid disorder and 31% developed two or
more chronic comorbidities. Five per cent of the IA pa-
tients developed five or more chronic comorbid disorders
during follow-up.
Table 2 shows only chronic diseases with a prevalence
of at least 2% in IA patients or controls. In total, 23%
of the IA patients and 18% of the control patients de-
veloped a cardiovascular disease (HR: 1.3 (1.2 – 1.5)Table 1 Baseline characteristics
IA patients Matched controls




Mean (sd) 55 (15) 55 (15)
Follow-up, years
Median (iqr) 2.8 (1.7-4.9) 2.7 (1.6-4.9)
Number of chronic diseases
at inclusion*












IA = inflammatory arthritis sd= standard deviation, iqr=interquartile range,
min= minimum, max=maximum.
*without IA.(Table 2). In total, 17% of the IA patients and 14% of the
control patients (HR: 1.3, 95% CI: 1.1 – 1.4) developed
musculoskeletal diseases. The frequency of the remaining
disease groups varied between 3 and 10% for IA patients
and 1 to 9% for control patients.
The highest risks to develop individual diseases for
IA patients compared to control patients were found
for anaemia (HR: 2.0), osteoporosis (HR: 1.9), COPD
(HR: 1.8), carpal tunnel syndrome (HR: 1.7), and per-
ipheral neuritis (HR 1.7).
The sensitivity analyses did not alter our findings, just
all effects were slightly reduced due to a loss of power.
So what do these results mean for a specific patient in
the general practice? To provide deeper insight into the
risk for a specific patient, the changes to develop COPD,
carpal tunnel syndrome, anaemia or heart failure were
calculated, see Figure 2 and 3. Women have a higher risk
to develop carpal tunnel syndrome compared to men,
for the other diseases it is the other way around. The
presence and the number of chronic diseases result in a
higher risk to develop another chronic disease. Addition-
ally, higher age resulted in a higher risk to develop an
additional chronic disease. For example: A male of 60
years at the onset of IA without additional chronic dis-
ease has a risk of 4% to develop COPD within 2.8 yrs. A
male aged 60 and with one or two chronic diseases at IA
onset has a risk of 5% risk to develop COPD within
2.8 yrs. A male aged 60 and with three or more chronic




Patients develop more chronic comorbid disorders after
the onset of IA than expected based on their age and
sex. In a median follow-up period of 2.8 years, 56% of the
IA patients have developed at least one chronic disease
compared to 46% in the matched control group. Of the
Table 2 Percentage of IA patients and control patients with new chronic comorbid disorders after diagnosis†
IA patients Matched controls HR crude 95% CI HR adjusted# 95% CI p-value
Main disease group*
Diagnosis
Blood and blood forming organs 3% 1% 2.0 (1.5-2.6) 1.9 (1.4-2.6) <0.001
Anaemia§ 2% 1% 2.0 (1.4-2.7) 2.0 (1.4-2.7) <0.001
Respiratory 7% 5% 1.6 (1.3-1.9) 1.5 (1.3-1.8) <0.001
COPD§ 4% 2% 1.8 (1.4-2.3) 1.8 (1.4-2.3) <0.001
Asthma (R96) 4% 3% 1.4 (1.1-1.8) 1.3 (1.0-1.7) 0.015
Neurological 8% 5% 1.5 (1.3-1.7) 1.4 (1.2-1.6) <0.001
Carpal tunnel syndrome (N93) 3% 2% 1.8 (1.4-2.4) 1.7 (1.3-2.3) <0.001
Peripheral neuritis/neuropathy (N94) 3% 2% 1.9 (1.5-2.5) 1.7 (1.3-2.2) <0.001
Psychological 9% 7% 1.3 (1.1-1.5) 1.3 (1.1-1.4) 0.003
Anxiety disorder§ 2% 1% 1.5 (1.1-2.1) 1.4 (1.0-2.0) 0.035
Depressive disorder (p76) 4% 3% 1.4 (1.1-1.8) 1.4 (1.1-1.7) 0.012
Cardiovascular 23% 18% 1.3 (1.2-1.4) 1.3 (1.2-1.5) <0.001
Phlebitis/thrombophlebitis (K94) 2% 1% 1.8 (1.3-2.4) 1.7 (1.2-2.3) 0.002
Varicose veins of leg (K95) 3% 2% 1.4 (1.1-1.8) 1.4 (1.1-1.8) 0.009
Hypertension§ 12% 9% 1.3 (1.1-1.5) 1.3 (1.1-1.5) 0.001
Heart failure (K77) 3% 2% 1.4 (1.1-1.9) 1.5 (1.1-2.0) 0.005
Digestive 5% 4% 1.3 (1.1-1.6) 1.3 (1.0-1.5) 0.02
Musculoskeletalb 17% 14% 1.3 (1.1-1.4) 1.3 (1.1-1.4) <0.001
Osteoporosis (L95) 3% 2% 1.9 (1.4-2.4) 1.9 (1.5-2.5) <0.001
Spinal Cord§ 9% 7% 1.4 (1.2-1.6) 1.3 (1.1-1.5) 0.001
Endocrinea 10% 9% 1.1 (0.9-1.2) 1.0 (0.9-1.2) 0.514
Other
Vertiginous syndrome (H82) 3% 2% 1.5 (1.2-1.9) 1.4 (1.1-1.8) 0.005
Cancer§ 5% 4% 1.3 (1.1-1.6) 1.3 (1.1-1.6) 0.004
Eczema§ 5% 4% 1.3 (1.0-1.6) 1.3 (1.0-1.6) 0.023
†Patients or controls may have several chronic comorbid disorders.
*Diagnoses included are listed in supplementary file. The ICPC codes within the cluster Cancer were excluded from the main groups.
HR = odds ratio, CI = confidence interval.
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most common newly developed comorbidities, whereas
the highest risk for individual diseases was found for an-
aemia, osteoporosis and COPD.
Comparison with existing literature
A study by Kapetanovic et al. found that 82% of the
RA patients developed a chronic comorbid disease after
disease onset [27]. This percentage is higher compared
to our study (56%), but the follow-up period was much
longer, up to twenty years, and they used self-reported
comorbidities instead of recorded in the EMR of the
GP.
Several recent studies demonstrated that patients with
IA have an increased risk of cardiovascular disease.10;11The result of our study supports this finding. However,
we did not find an increased risk for some common
reported cardiovascular diseases in patients with IA,
like ischaemic heart disease, atrial fibrillation flutter or
stroke [10-12]. These diseases might develop after a longer
period than our median follow-up duration of nearly three
years. We found a small but increased risk for cancer in
IA patients; this finding is supported by a meta-analysis
of Smitten et al. who found increased risks for several
cancer types in IA patients [28].
We found an increased risk that IA patients develop
COPD. This is in line with another study [29]. Patients with
COPD have partly the same clinical and pathophysiological
characteristics as patients with IA, like inflammation.












40 50 60 70 40 50 60 70 40 50 60 70 40 50 60 70
Absolute risk for a chronic disease in male 
at onset of IA
3 or more chronic diseases
1 or 2 chronic diseases
No chronic diseases
Heart failure Carpal tunnel  
syndrome
COPDAnemia
Figure 2 The absolute risk on a chronic disease accumulated for the categories no. 1 or 2 and 3 or more diseases. When no bar is
presented, the risk for developing a new chronic disease is 0%. Absence of the other two categories means no additional risk with respect to the
previous category. For example: a 60-year old male with no additional chronic disease has 2% risk to develop anemia. A 60-year old male with
one or two chronic diseases at IA onset has also 2% risk to develop anemia -no additional bar for one or two chronic diseases is presented-. A
60-year old male with three or more chronic diseases at IA onset has 3% risk to develop anemia.
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http://www.biomedcentral.com/1471-2296/14/199and exacerbations occur in both IA and COPD [30]. Fi-
nally, both diseases share risk factors like smoking and
physical inactivity. Apart from COPD, inflammation could
also play a role in the development of osteoporosis, an-
aemia, carpal tunnel syndrome and cardiovascular dis-











40 50 60 70 40 50 60 70
Absolute risk for a ch
at onse
Heart failure Carpal tunnel  
syndrome
Figure 3 The absolute risk of developing a new chronic disease stack
bar is presented, the risk for developing a new chronic disease is 0%. Abse
category. For example: a 70-year old female with no additional chronic dise
with one or two chronic diseases at IA onset has 5% risk to develop COPD
has 6% risk to develop COPD.found in the current study. Malnutrition caused by in-
flammation and hormonal factors may subsequently play
a role in the development of osteoporosis as well as the
use of glucocorticoids leading to glucocorticoid-induced
osteoporosis [34-36]. Carpal tunnel syndrome might be
the result of IA related inflammation as well, as40 50 60 70 40 50 60 70
ronic disease in female 
t of IA
3 or more chronic diseases
1 or 2 chronic diseases
No chronic diseases
Anemia COPD
ed for the categories no. 1 or 2, and 3 or more diseases. When no
nce of a category means no additional risk with respect to de previous
ase at IA onset has 4% risk to develop COPD. A 70-year old female
. A 70-year old female with three or more chronic diseases at IA onset
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can also cause increased pressure in the carpal tunnel
[33].
In our study, over half of all IA patients developed one
or more new diseases within a median follow-up period
of nearly 3 years. Furthermore, the newly developed dis-
eases represent a broad spectrum of diseases, so no fixed
sequence or combinations of new diseases was observed.
This is confirmed in studies among patients with multi-
morbidity, as patients with a chronic disease often have
more than one chronic disease, as multimorbidity occurs
in more than two-thirds of the elderly with common
chronic diseases [37]. Additionally, another study found
that the cumulative incidence rates of one or more new
morbidities rapidly increase with the number of morbid-
ities already present [38,39]. The sequence of developing
additional chronic comorbid disorders may be influenced
by different factors like medication use, the combin-
ation of disease already acquired, or a common underlying
mechanism [40].
Strengths and limitations
A strength of this study is that all Dutch citizens are
listed within a general practice, and the GP is the first
professional to be consulted for health problems. There-
fore, the GP has a complete view on the patients’ lifetime
health status.37 Moreover, Dutch GPs obtain information
of diagnosis made by the medical specialist, since the
Dutch guidelines for optimising GP-medical specialist
communication support medical specialists to inform GPs
about the referred patient. Beside these advantages, this
study has some limitations. First, we have excluded gout,
osteoarthritis and psoriasis from the results, because these
diseases are too much interrelated with IA. Therefore,
it is difficult to conclude whether it is an isolated disease
or part of IA. Patients with a combination of one of these
diseases and an IA suspicion (L88 code registered) could
have been misclassified. Second, we have used the ICPC
code L88 to identify possible IA patients and we have used
an algorithm to distinguish IA from non-IA. However, it
was not possible to exclude all non-IA patients, this could
have resulted in an underestimation of the true hazard ra-
tios. Furthermore, the follow-up of three years may be too
short a period to develop some chronic comorbid disor-
ders, like e.g. ischaemic heart disease.
Implications for research and/or practice
More than half of the patients with IA developed one or
more chronic diseases after the onset of IA. As inflamma-
tory processes are a common risk factor for several other
comorbidities, tight control of inflammation seems of
great importance. Also, attention for other common or
specific risk factors, like smoking for COPD, or gluco-
corticoid use for osteoporosis, can improve the primary orsecondary preventive care for IA patients and may prevent
or postpone the occurrence of some comorbidities. The
attention for the development of chronic diseases in older
patients should be intensified and also the presence of
chronic diseases should be taken into account.
Conclusion
Patients with IA develop more chronic comorbid disor-
ders after diagnosis of IA than is to be expected based on
age and sex. The most frequent chronic comorbidities ob-
tained after diagnose can be categorised in cardiovascular,
musculoskeletal and neurological diseases. Since comor-
bidity has an impact on the disease course, on quality of
life, and possibly on the treatment itself, preventive care
should become a more explicit treatment target.Additional files
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Additional file 2: Table S2. Overview of ICPC codes that were
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